Skip to main content Skip to search Skip to main navigation

ICH: ICH Q3C(R8) Guideline for Residual Solvents contains new PDEs

ICH published the revised version (Step 4) of the ICH Q3C(R8) Guideline on Impurities: Guideline for Residual Solvents on 22 April 2021.

The Permitted Daily Exposure (PDE) values for the following substances were added:  

  • 2-Methyltetrahydrofuran (50 mg/day) 
  • Cyclopentyl methyl ether (15 mg/day)  
  • Tertiary butyl alcohol (35 mg/day) 

The PDE values were developed by the relevant Expert Working Group (EWG). On 25 March 2020, ICH already published the document for public consultation under Step 2 (we reported). The values proposed then have been adopted as final and the Step 4 version has not been changed compared to the draft document. This allows implementation to take place in the ICH regions. This ICH process, which is conducted under "Step 5", concludes the revision. 

Toxicity details:  

  • Methyltetrahydrofuran was found to be non-genotoxic in a mutation assay with bacteria, human lymphocytes and rats. No data are available on carcinogenicity. Reproductive toxicity and repeated-dose toxicity were not observed. The product was classified in solvent class 3.  
  • For cyclopentyl methyl ether, no toxicity in humans was found. Likewise, no genotoxic potential was found. Again, no data are available on carcinogenicity. No statements could be made on reproductive and developmental toxicity on the basis of data available to date. The product was classified as a class 2 solvent.  
  • For tertiary butyl alcohol, no genotoxicity was found either. The data on carcinogenicity do not allow any precise conclusions to be drawn with regard to the effect on humans, while changes in the renal tubules were found in rats. No precise statements could be made on reproductive toxicity either, but moderate transient systemic toxicity was found in rats. The product was classified as a class 2 solvent.  

In a revision process, further PDE values are to be gradually added as new toxicological data for solvents become known. 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ANVISA: Expands Recognition of Foreign GMP Authorities

ANVISA: Expands Recognition of Foreign GMP Authorities

Brazilian health authority ANVISA has updated the requirements for the recognition of Equivalent Foreign Regulatory Authorities (AREE) and the administrative procedures for Good Manufacturing Practice (GMP) certification (CBPF) through Normative Instruction IN 451/2026. The aim is to streamline and accelerate regulatory processes.
Read more
EDQM: Guidance on Reporting on Disappearances of Medicinal Products

EDQM: Guidance on Reporting on Disappearances of Medicinal Products

The EDQM has published guidance supporting the implementation of Recommendation CM/Rec(2024)3 on reporting medicinal products that disappear from the legal supply chain due to theft, loss or diversion. The initiative follows a European survey that identified shortcomings in reporting and co-ordination of such incidents.

Read more
Damage Control: Complaints and Recalls

Damage Control: Complaints and Recalls

Complaint handling and product recalls are important components of the Pharmaceutical Quality System (PQS). They serve to identify defective medicinal products and ensure that appropriate measures are taken to protect patient safety, as required by law and the competent supervisory authority.

Read more
What are the Phases of a Working Cycle During a Steam Sterilisation Process?

What are the Phases of a Working Cycle During a Steam Sterilisation Process?

Here's the answer:
Read more
EMA: 9 New Nitrosamines for Appendix 1

EMA: 9 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

The European Medicines Agency (EMA) published an update to its “Quality of Medicines: Questions and Answers – Part 2”. The revision concerns the section on “Reduced testing of incoming starting materials”.
Read more
Previous
Next